Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the New England Journal of ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Obesity specialists say first-generation anti-obesity medications often get a ‘bad wrap,’ but these drugs can be effective ...

The FDA has approved the first at-home cervical cancer test and weight loss drugs could reduce obesity related cancers.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

SYNT-101 introduces an innovative method for weight loss by temporarily redirecting nutrient absorption in the small ...

A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...